Liquid biopsy specialist ANGLE plc (AIM: AGL) (OTCQX: ANPCY) announced on Wednesday that it has entered a collaboration with Myriad Genetics Inc (NASDAQ: MYGN) to assess the feasibility of using circulating tumour cell (CTC) DNA derived from ANGLE's Parsortix system alongside Myriad's existing tissue-based diagnostic test.

Under the agreement, ANGLE's R&D team will process blood samples from cancer patients using Parsortix to capture and harvest intact cancer cells. The resulting CTC-DNA will then be compared with matched patient tissue samples analysed through Myriad's assay.

ANGLE's Parsortix PC1 System, FDA cleared and patent protected, enables downstream analysis of circulating tumour cells, including imaging, proteomic, genomic and transcriptomic profiling. The company's commercial activities span diagnostic products and clinical services, with over 110 peer-reviewed publications validating the system's performance.

Myriad Genetics is a global leader in molecular diagnostics and precision medicine, focused on improving patient outcomes through advanced genetic testing solutions.